Effects of different human chorionic gonadotrophin preparations on trophoblast differentiation.
Recent evidence from the literature suggested that hCG preparations purified from urine of pregnant women, which are widely used in in vitro studies and IVF programs, may contain contaminants such as EGF. To determine the putative biological effects of the contaminating growth factor, we here investigated distinct trophoblast differentiation processes in the presence of various hCG compounds. Western blot analyses indicated that treatment of trophoblastic SGHPL-5 cells and purified term trophoblasts with potentially EGF-contaminated hCG (hCG-A) resulted in auto-phosphorylation of the EGF receptor at tyrosine 1173 whereas supplementation of another urine-purified hCG preparation (hCG-B), recombinant holo-hCG or recombinant alphahCG had no effects. Phosphorylation was specifically blocked by the EGF receptor inhibitor PD153035. Urinary hCG-A was most effective in promoting invasion of SGHPL-5 cells through Matrigel-coated transwells, but increased invasiveness was also observed in the presence of hCG-B or recombinant holo-hCG. Similarly, the extent of syncytialisation of term trophoblasts, quantitated by nuclei in desmoplakin-negative areas, was highest upon addition of hCG-A or recombinant EGF as a control. PD153035 reduced invasion and fusion of trophoblasts supplemented with hCG-A, but did not diminish the effects provoked by hCG-B. In conclusion, the data suggest that the EGF contamination of hCG considerably affects trophoblast function. Experiments using EGF-free hCG preparations demonstrate that the hormone increases trophoblast invasion and syncytialisation.
Saleh
L
L
Department of Obstetrics and Gynecology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna A-1090, Austria.
Prast
J
J
Haslinger
P
P
Husslein
P
P
Helmer
H
H
Knöfler
M
M
D002454:Cell Differentiation / Q000187:drug effects*; D002478:Cells, Cultured; D006063:Chorionic Gonadotropin / Q000494:pharmacology*; D066246:ErbB Receptors / Q000187:drug effects*; D005260:Female; D015292:Glycoprotein Hormones, alpha Subunit / Q000494:pharmacology; D006801:Humans; D010766:Phosphorylation / Q000187:drug effects; D011247:Pregnancy; D011994:Recombinant Proteins / Q000494:pharmacology; D014327:Trophoblasts / Q000166:cytology / Q000187:drug effects*
D006063:Chorionic Gonadotropin; D015292:Glycoprotein Hormones, alpha Subunit; D011994:Recombinant Proteins; D066246:ErbB Receptors